NTC
NBIX icon

NF Trinity Capital’s Neurocrine Biosciences NBIX Stock Holding History

NF Trinity Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-105,202
Closed -$4.84M – 51
2017
Q2 		$4.84M Sell
105,202
-78,000
-43% -$3.78M 0.69% 32
2017
Q1 		$7.93M Hold
183,202
– – 1.07% 23
2016
Q4 		$7.09M Buy
183,202
+120,202
+191% +$5.44M 1% 23
2016
Q3 		$3.19M Buy
+63,000
New +$3.14M 0.36% 41

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

NF Trinity Capital's NBIX Position: Q3 2017 in Review

NF Trinity Capital sold out of Neurocrine Biosciences (NBIX) in Q3 2017, closing a stake of 105,202 shares — an estimated $4.84M sold.

NF Trinity Capital first reported a position in NBIX in Q3 2016 and held it in 4 quarters. The position peaked at $7.93M in Q1 2017. 223 funds tracked by Wall St. Rank hold NBIX as of Q3 2017.

  • NF Trinity Capital reported no remaining Neurocrine Biosciences position as of Q3 2017 after selling out during the quarter.
  • NF Trinity Capital sold 105,202 Neurocrine Biosciences shares in Q3 2017, an estimated $4.84M.
  • NF Trinity Capital first reported a position in Neurocrine Biosciences in Q3 2016 and held it in 4 quarters.
  • NF Trinity Capital's Neurocrine Biosciences position peaked at $7.93M in Q1 2017.
  • 223 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2017.

Based on NF Trinity Capital's 13F filing for Q3 2017, filed 7 Nov 2017.